JPRN-UMIN000025163已完成未知
A Double Blind, Randomized Placebo-Controlled Study of Clinical Efficacy of Melon-GliSODin for the Treatment of Aging-related Dysfunction in Motor Organs - Efficiency of GliSODin
Department of Orthopaedic Surgery, Juntendo Tokyo Koto Geriatric Medical Center0 个研究点目标入组 50 人开始时间: 2016年12月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Volunteer with diseases including internal midicine, psychogenic disorders, neuromuscular diseases, postoperative state of orthopaedic surgery, allergy against melon and wheat.
研究者
相似试验
已完成
3 期
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer ( MONALEESA 3)C50.9Advanced Breast Canceradvanced breast cancerLBCTR2019080232ovartis Pharma Services Inc.6
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2019-004941-34-ITGENFIT150
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2019-004941-34-FRGENFIT150
招募中
3 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidPrimary Biliary Cholangitis2024-512232-30-00Ipsen Pharma61
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 10019805 - Hepatobiliary disordersPrimary Biliary CholangitisEUCTR2019-004941-34-DEIPSEN Pharma SAS161